Log in

LON:SLN - Silence Therapeutics Share Price, Forecast & News

GBX 560
+5.00 (+0.90 %)
(As of 12/11/2019 08:26 AM ET)
Today's Range
550
Now: GBX 560
560
50-Day Range
271
MA: GBX 426.74
605
52-Week Range
40
Now: GBX 560
613.80
Volume17,184 shs
Average Volume13,380 shs
Market Capitalization£438.87 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-34576900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 22.79 per share
Book ValueGBX 38.10 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap£438.87 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SLN News and Ratings via Email

Sign-up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.


Silence Therapeutics (LON:SLN) Frequently Asked Questions

What is Silence Therapeutics' stock symbol?

Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics plc (LON:SLN) issued its quarterly earnings results on Tuesday, September, 11th. The company reported ($12.40) earnings per share (EPS) for the quarter. View Silence Therapeutics' Earnings History.

What is the consensus analysts' recommendation for Silence Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Silence Therapeutics.

Has Silence Therapeutics been receiving favorable news coverage?

News coverage about SLN stock has trended positive on Wednesday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Silence Therapeutics earned a news sentiment score of 2.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future. View News Stories for Silence Therapeutics.

Who are some of Silence Therapeutics' key competitors?

What other stocks do shareholders of Silence Therapeutics own?

Who are Silence Therapeutics' key executives?

Silence Therapeutics' management team includes the folowing people:
  • Dr. David Horn Solomon, CEO & Director (Age 59)
  • Dr. Rob Quinn, Chief Financial Officer
  • Dr. Mark Cameron, Head of Chemistry
  • Mr. Richard Jenkins, Head of Clinical Devel.

How do I buy shares of Silence Therapeutics?

Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Silence Therapeutics' stock price today?

One share of SLN stock can currently be purchased for approximately GBX 560.

How big of a company is Silence Therapeutics?

Silence Therapeutics has a market capitalization of £438.87 million. View Additional Information About Silence Therapeutics.

What is Silence Therapeutics' official website?

The official website for Silence Therapeutics is http://www.silence-therapeutics.com/.

How can I contact Silence Therapeutics?

Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900.


MarketBeat Community Rating for Silence Therapeutics (LON SLN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  178 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  344
MarketBeat's community ratings are surveys of what our community members think about Silence Therapeutics and other stocks. Vote "Outperform" if you believe SLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: Capital Gains

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel